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Purpose: To compare cerebral blood flow (CBF) and cerebrovascular reserve (CVR) 
quantification from Turbo‐QUASAR (quantitative signal targeting with alternating 
radiofrequency labeling of arterial regions) arterial spin labeling (ASL) and single 
post‐labeling delay pseudo‐continuous ASL (PCASL).
Methods: A model‐based method was developed to quantify CBF and arterial transit 
time (ATT) from Turbo‐QUASAR, including a correction for magnetization transfer 
effects caused by the repeated labeling pulses. Simulations were performed to assess 
the accuracy of the model‐based method. Data from an in vivo experiment conducted 
on a healthy cohort were retrospectively analyzed to compare the CBF and CVR 
(induced by acetazolamide) measurement from Turbo‐QUASAR and PCASL on the 
basis of global and regional differences. The quality of the two ASL data sets was 
examined using the coefficient of variation (CoV).
Results: The model‐based method for Turbo‐QUASAR was accurate for CBF estimation 
(relative error was 8% for signal‐to‐noise ratio = 5) in simulations if the bolus duration was 
known. In the in vivo experiment, the mean global CVR estimated by Turbo‐QUASAR 
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1 |  INTRODUCTION
Arterial spin labeling (ASL) is an MRI technique that allows 
the quantification of cerebral blood flow (CBF).1 Under certain 
acquisition conditions, it is also possible to quantify other pa-
rameters, such as arterial transit time (ATT) and arterial blood 
volume.2 Although pseudo‐continuous ASL (PCASL) with a 
single post‐labeling delay (PLD) has been recommended as 
the standard implementation,3 it can be sensitive to changes in 
ATT, which varies in different regions of the brain, potentially 
affecting the precise quantification of CBF.4 Given that ASL 
does not expose the subject to ionizing radiation and is read-
ily repeatable and noninvasive, it can also be used to measure 
cerebrovascular reserve (CVR), an important biomarker re-
flecting the maximal change in CBF that can be achieved rela-
tive to the baseline CBF in response to a vasoactive stimulus.5 
However, if the recommended ASL implementation is utilized 
in CVR experiments, in which data need to be collected under 
different induced blood flow conditions, CBF and CVR might 
be wrongly estimated because of the change in ATT caused 
by the varying arterial flow velocity.6 For example, in a cere-
brovascular reactivity study using multi‐PLD PCASL, the re-
searchers demonstrated a significant increase in CBF between 
3.5% and 27.8% and a significant decrease in ATT between 
3.3% and 7.7% during hypercarbia, suggesting that variations 
in ATT should be controlled for the accurate quantification of 
CBF in CVR studies.7 Additionally, the inversion efficiency 
of PCASL is sensitive to changes in velocity of the inflow-
ing blood in the labeling plane,8 potentially leading to further 
inaccuracy in the quantified CBF and CVR. Thus, both ATT 
and inversion efficiency might be confounds to CVR quanti-
fication,9 making single‐PLD PCASL a potentially less desir-
able tool. In contrast to PCASL, the inversion efficiency of 
pulsed ASL (PASL) is less sensitive to changes in blood flow 
velocity,10 and when a multi‐PLD or multi‐TI (inversion time) 
imaging technique is utilized to simultaneously estimate ATT, 
its variation can be corrected for.11 However, typical PASL 
labeling gives rise to far lower signal‐to‐noise ratio (SNR) 
than PCASL attributable to the shorter bolus duration as well 
as the influence of T1 decay on the label.
12
Recently, a novel PASL technique, dubbed Turbo‐
QUASAR (quantitative signal targeting with alternating 
radiofrequency labeling of arterial regions), has been de-
veloped with the aim of improving the SNR of conventional 
PASL techniques, by creating a series of boluses of labeled 
blood‐water in a single ASL experiment, while retaining the 
ability to estimate ATT by utilizing a multi‐TI Look‐Locker 
readout.13 Although preliminary work on Turbo‐QUASAR 
showed comparable SNR with PCASL and full brain 
coverage,13 it remains unknown whether Turbo‐QUASAR 
provides effective and accurate CBF measurement. In partic-
ular, because of the repeated radiofrequency (RF) pulses in 
the label and control experiments of Turbo‐QUASAR, mag-
netization transfer (MT) effects could potentially affect the 
estimation accuracy of CBF.14,15 Given that Turbo‐QUASAR 
combines the features of PASL and multi‐TI acquisition, it 
may potentially be a suitable ASL‐based technique for CVR 
quantification where substantial variation in flow velocity 
and ATT might be confounding because of the administration 
of a vasoactive stimulus.
The aim of this work was to (1) develop a model‐based 
method for CBF and ATT quantification for Turbo‐QUASAR 
and (2) investigate the application of Turbo‐QUASAR for 
CVR measurement. Simulations were performed to evaluate 
the estimation accuracy and sensitivity of parameter estima-
tion to variations in ATT and bolus duration, as might be ex-
pected within a study population and with variation in blood 
flow velocity. Data from an in vivo experiment collected on 
a healthy cohort were retrospectively analyzed to compare 
the CBF and CVR (induced by acetazolamide administra-
tion) measurement between Turbo‐QUASAR and single‐PLD 
PCASL on a full brain and regional basis. The quality of the 
PCASL and Turbo‐QUASAR data was assessed by the coeffi-
cient of variation (CoV) of the estimated CBF values.
and PCASL was between 63% and 64% and not significantly different. Although global 
CBF values of the two ASL techniques were not significantly different, regional CBF dif-
ferences were found in deep gray matter in both pre‐ and postacetazolamide conditions. 
The CoV of Turbo‐QUASAR data was significantly higher than PCASL.
Conclusion: Both ASL techniques were effective for quantifying CBF and CVR, 
despite the regional differences observed. Although CBF estimated from Turbo‐
QUASAR demonstrated a higher variability than PCASL, Turbo‐QUASAR offers 
the advantage of being able to measure and control for variation in ATT.
K E Y W O R D S
arterial spin labeling, cerebral blood flow, cerebrovascular reserve, pseudo‐continuous arterial spin 
labeling, pulsed arterial spin labeling, Turbo‐QUASAR
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2 |  THEORY
2.1 | Turbo‐QUASAR sequence
As an improvement of the QUASAR method,2,16 Turbo‐
QUASAR was designed to overcome the low SNR of PASL 
when compared to PCASL by applying a series of labeling 
pulses to create a longer effective bolus duration.13 These 
labeling pulses were inserted between readout (also replacing 
the QUIPPS II pulse used in QUASAR) to maintain the mag-
netization level of the tracer for a longer period than conven-
tional PASL techniques, as shown in Figure 1, thus increasing 
the overall SNR of the resulting ASL data. Figure 1A shows 
the different labeling techniques and the associated arterial 
input function for QUASAR, Turbo‐QUASAR, and PCASL. 
In essence, the total bolus duration of each Turbo‐QUASAR 
F I G U R E  1  Turbo‐QUASAR techniques and pulse sequence diagrams. (A) In QUASAR, only one short‐duration bolus is created (shown 
by the typical PASL AIF curve in red) and a Look‐Locker readout is performed to acquire multi‐PLD (black dash lines) ASL data. In Turbo‐
QUASAR, labeling (blue dash line) and acquisition (black dash line) are interleaved and multiple boluses are created. Hence, a summation of 
multiple boluses creates a higher SNR. In PCASL, the inflowing spins are labeled continuously, creating a longer duration bolus with the typical 
“rectangular” PCASL AIF. (B) Tissue kinetic curve for QUASAR ASL (green), Turbo‐QUASAR (blue), and PCASL (purple). (C) In Turbo‐
QUASAR, each TR consists of six label/control pulses and 11 TIs. Null pulses were used in the control condition to minimize the impact of MT 
effects. (D) Presaturation, label/control pulses, crushing gradients in three directions, and Look‐Locker readout
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experiment is the summation of the duration of each sub‐
bolus created by each RF pulse. Because of the multiple la-
beling pulses and the interleaving of labeling and imaging, 
the QUIPPS II style bolus saturation pulse used in QUASAR 
cannot be applied in Turbo‐QUASAR, which might lead 
to an uncertain duration for each of the individual boluses. 
As in QUASAR, the readout scheme of Turbo‐QUASAR is 
Look‐Locker, but the time between each successive readout 
(ΔTI) was chosen to be longer than QUASAR in order to 
allow enough time for the inflowing blood‐water inverted by 
one labeling pulse to leave the labeling region before the sub-
sequent labeling pulse. While maintaining the same time for 
acquiring each slice, this not only allows more slices to be ac-
quired to reach a nearly full brain coverage, but also reduces 
rapid signal decay from the repeated Look‐Locker excitations. 
Supporting Information Figure S1B shows the kinetic curve 
of the signal in the tissue from QUASAR, Turbo‐QUASAR, 
and PCASL. Given that Turbo‐QUASAR includes multiple 
labeling pulses, the total effective bolus duration (and SNR) 
is much larger than QUASAR. Consistent with the original 
Turbo‐QUASAR work,13 we refer to the bolus duration as 
the total effective duration of all labeling pulses in a Turbo‐
QUASAR experiment. We define sub‐bolus duration (SBD) 
as the duration of the tracer created by a single labeling pulse. 
Given that each labeling pulse is applied exactly between 
each successive Look‐Locker acquisition, the SBD should be 
identical to the time between each readout (ΔTI of 600 ms in 
this study). This can be achieved by optimizing the width of 
the labeling slab and considering the flow velocity such that 
all labeled spins would flow out of the labeling region be-
fore the next labeling pulse is applied. Under such conditions, 
the bolus duration of Turbo‐QUASAR can be determined by 
summing up the duration of all the sub‐boluses. Under non-
ideal conditions (e.g., suboptimal choice of labeling thick-
ness for a given arterial blood velocity), the SBD might be 
shorter than expected. Another distinctive feature of Turbo‐
QUASAR is that slices are acquired from different locations 
in each repeat to achieve full‐brain coverage while keeping 
the same effective temporal resolution with QUASAR for the 
accurate estimation of ATT. The detailed description of this 
strategy is explained in Supporting Information Figure S1.
2.2 | Calibration
The absolute quantification of CBF requires the measurement 
of equilibrium magnetization of the arterial blood (M0a), 
which can be computed from the equilibrium magnetization 
of the tissue (M0t). Similar to QUASAR, M0t can be estimated 
by fitting the control images to a saturation recovery model.16 
In Turbo‐QUASAR, given that the labeling pulses are applied 
repeatedly between the Look‐Locker readout, the recovery of 
the static tissue signal is influenced by two effects as shown 
in Supporting Information Figure S2: (1) affected by both 
Look‐Locker readout and cumulative MT effects attributed 
to the repeatedly labeling pulse; (2) affected by Look‐Locker 
readout alone. Although the correction for the Look‐Locker 
effect follows the same principle in QUASAR,16 a correction 
for the MT effects is needed for estimating M0t in Turbo‐
QUASAR. Specifically, the magnetization of the spins in the 
static tissue during the readout can be modeled by a modified 
saturation recovery model that separates signals affected by 
both MT effects and Look‐Locker readout during the period 
where labeling pulses are being applied (t≤ tI), and by Look‐
Locker readout alone (t> tI) (Equation 1):
The definitions of the terms used here can be found in 
Table 1. While it is expected that there would be voxel‐
wise variation in T1 and therefore T ′1t in the brain, T
′
1t_MT
 
would also be expected to vary with proximity to the label-
ing region, as shown in Supporting Information Figure S2. 
Subsequently, M0t and T1t (without the influence of MT and 
Look‐Locker effects) can be estimated from M′
0t
 and T ′
1t
 by 
applying the correction method on Look‐Locker effects used 
in QUASAR.16
2.3 | Tissue kinetic model
The ASL difference signal of Turbo‐QUASAR can be con-
sidered as the summation of the signal from each sub‐bolus 
(as illustrated in Figure 1) that can be described using the 
general kinetic model.17 The definitions of the terms used can 
be found in Table 1. The arterial input function (AIF; ci (t)) 
of the ith sub‐bolus is given by Equation 2:
The residue function remains the same as in QUASAR.16 
For the magnetization decay function mi (t), both the Look‐
Locker readout and MT effects affect the decay of the label 
in tissue. For the ith sub‐bolus that has arrived at the tissue 
region, the decay function can be approximated by Equation 3:
that is, labeled blood‐water present in the tissue while label-
ing is continuing subject to MT effects and thus experiences 
an accelerated relaxation modeled by the T ′
1t_MT
 time constant 
(1)M (t)=
⎧
⎪⎨⎪⎩
M�
0t_MT
⋅ A ⋅
�
1−e
−
t
T�
1t_MT
�
, 0< t≤ tI
M�
0t
−
�
M�
0t
−MI
�
⋅ A ⋅ e
−
t−tI
T�
1t , t> tI
(2)ci (t)=
⎧
⎪⎪⎨⎪⎪⎩
0, 0< t< i ⋅ΔTI+ATT
e
−
t−i⋅ΔTI
T1a , i ⋅ΔTI+ATT ≤ t< i ⋅ΔTI+ATT +𝜏
0, i ⋅ΔTI+ATT +𝜏 ≤ t
(3)mi (t)=
⎧⎪⎨⎪⎩
e
−
t
T�
1t_MT , 0< t<max
�
0,tI − i ⋅ΔTI−ATT
�
e
−
t
T�
1t , tI ≤ t
   | 735ZHAO et Al.
that can be estimated voxelwise from the control images. 
Incorporating the analytical solution of the tissue kinetic model 
for PASL,18 the tissue signal of each sub‐bolus can be expressed 
by Equation 4:
where R�
MT
=1∕T �
1t_MT
−1∕T1 , R
� =1∕T �
1t
−1∕T1 , F=2 ⋅ ⋅M0, ⋅ f∕. 
The four components of ΔMi (t) represent: (1) before the arrival 
of the the ith sub‐bolus (2) from the arrival of the the ith sub‐
bolus to the end of the the ith sub‐bolus, in which the signal is 
influenced by MT and Look‐Locker effects (3) from the end of 
the ith sub‐bolus to MT effects terminate (the final sub‐bolus 
does not have this part) (4) after the MT effects terminate, in 
which the signal is only affected by Look‐Locker readout pulses. 
Finally, the acquired signal ΔM (t) of Turbo‐QUASAR is the 
summation of the signal of each sub‐bolus ΔM (t)=
∑
ΔMi (t).
3 |  METHODS
3.1 | Simulation experiments
Three simulation experiments were conducted to investigate 
the accuracy of the model‐based method for Turbo‐QUASAR 
under various flow conditions. Simulated Turbo‐QUASAR 
(4)ΔMi (t)=
⎧
⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
0, 0 < t < i ⋅ΔTI+ATT
F⋅e
−(t−i⋅ΔTI)
T�
1t_MT
R�
MT
⋅
�
eR
�
MT
⋅(t−i⋅ΔTI) −eR
�
⋅ATT
�
, i ⋅ΔTI+Δt≤ t < i ⋅ΔTI+ATT +𝜏
F⋅e
−(t−i⋅ΔTI)
T�
1t_MT
R�
MT
⋅
�
eR
�
MT
⋅(Δt+𝜏) −eR
�
⋅ATT
�
, i ⋅ΔTI+Δt+𝜏 ≤ t < tI − i ⋅ΔTI−ATT −𝜏
F⋅e
−(t−i⋅ΔTI)
T�
1t
R�
⋅
�
eR
�
⋅(Δt+𝜏) −eR
�
⋅ATT
�
, tI − i ⋅ΔTI−ATT −𝜏 ≤ t
T A B L E  1  Parameter definitions
Term Definition
A Saturation efficiency
 Inversion efficiency
c
i
(t) AIF of the ith sub‐bolus
 (v) T1 corrected efficiency for a spin with velocity v
f CBF
L Width of the labeling slab in Turbo‐QUASAR
mi(t) Magnetization decay function of the ith sub‐bolus
M0a Equilibrium magnetization of the arterial blood
M0t Equilibrium magnetization of the tissue
M
′
0t
Equilibrium magnetization of the tissue affected by Look‐Locker effects
M
′
0t_MT
Equilibrium magnetization of the tissue affected by MT and Look‐Locker effects
ΔM (t) Tissue signal of the ASL data
ΔM
i
(t) Tissue signal of the ith sub‐bolus
MI Signal at tI
ATT Arterial transit time
ΔTI Time between each readout
 Sub‐bolus duration (SBD)
 Blood‐water partition coefficient
T1a T1 relaxation time of the arterial blood
T
′
1t
T1 relaxation time of the tissue affected by Look‐Locker effects
T
′
1t_MT
T1 relaxation time of the tissue affected by MT and Look‐Locker effects
t
I
Time at which MT effects terminate
v Flow velocity
vmax Maximum velocity in the center of the laminar flow profile
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difference data were created using the parameters listed in 
Table 2. A reference signal value was assumed to be the high-
est signal intensity of the kinetic curve generated by these 
parameters with one sub‐bolus. Noise was added to the simu-
lated data assuming white noise according to ℕ (0, SD) where 
SD=Reference signal∕SNR with 1000 realizations.
Experiment 1 examined the accuracy of CBF estimation 
using model‐based analysis of Turbo‐QUASAR under differ-
ent SNRs. The level of SNR was manipulated by (1) varying 
the number of sub‐boluses from 1 to 7 in order to vary bolus 
duration and (2) varying the amount of noise by changing 
the SD. For analysis, the SBD () was set to be 600 ms (same 
T A B L E  2  Parameter values used in simulations and in vivo experiments
Parameter Value
All simulation experiments
CBF (mL/100 g/min) 60
ATT (ms) 700
TI (ms) 40, 640, …, 6040
Tissue T1 (ms) 1300
Arterial blood T1 (ms) 1650
Simulation experiment 1
No. of sub‐boluses 1, 2, …, 7
SBD () (ms) 600
SNR 10, INF
Simulation experiment 2
No. of sub‐boluses 7
SBD () (ms) 300, 400, 500, 600
Variations added to SBD (ms) ℕ (0, 10)
SNR 5, 10, 50, 100
Simulation experiment 3
No. of boluses 7
SBD () (ms) 600
SNR 5, 10, 50, 100
ATT (ms) 800, 1000, 1200
In vivo experiment using Turbo‐QUASAR
CBF (mL/100 g/min) (0, 1012)a
ATT (ms) (700, 10–1)a
Tissue T1 (ms) Estimated from the control data
Arterial blood T1 (ms) 1650
Total number of sub‐boluses 6
SBD () (ms) Estimated from PC‐MRI data
Blood‐water partition coefficient 0.98
Inversion efficiency 0.91
In vivo experiment using PCASL
CBF (mL/100 g/min) (0, 1012)a
ATT (ms) 1300
PLD (ms) 1800
Bolus duration (ms) 1800
Tissue T1 (ms) 1300
Arterial blood T1 (ms) 1650
Blood‐water partition coefficient 0.98
Inversion efficiency estimated from PC‐MRI data
aValues indicate the mean and standard deviation of the Gaussian prior used in the model fitting. 
Abbreviation: INF, infinity. 
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as in the in vivo experiment) and not estimated by the model‐
based analysis. The mean and the standard deviation of the 
estimated CBF were computed.
Experiment 2 investigated the accuracy of the model‐
based method under various flow conditions. As discussed, 
the SBD in Turbo‐QUASAR is designed to be equal to the 
time period between each successive RF pulse under normal 
flow velocity and laminar flow. In conditions where the flow 
becomes more rapid, however, the effective SBD would de-
crease. To model the rapid flow, the simulated SBD () was 
set to 300, 400, 500, and 600 ms plus a random variation 
drawn from a normal distribution, ℕ(0, 10 ms). Given that 
the time between each readout (∆TI) used in the in vivo data 
was 600 ms, it was not possible for SBD to exceed 600 ms, 
thus longer SBDs were not considered in the simulation ex-
periments. Data were generated over a range of SNRs: 5, 10, 
50, and 100. CBF, ATT, and SBD were estimated using the 
model‐based technique in four ways:
1. Default SBD Step 1: CBF and ATT were estimated 
assuming the default value of SBD ( =600 ms, without 
the added random variation).
2. Default SBD Step 2: CBF, ATT, and SBD were all 
estimated using the results from step 1 as the priors for 
the model‐fitting process and assuming a constant value 
of SBD ( =600 ms, without the added random variation).
3. Corrected SBD Step 1: CBF and ATT were estimated using 
the simulated SBD values ( =300, 400, 500, or 600 ms 
without the added random variation).
4. Corrected SBD Step 2: CBF, ATT, and SBD were all 
estimated using the results from step 3 as the priors for the 
model‐fitting process and using the simulated SBD values 
( =300, 400, 500, or 600 ms without the added random 
variation).
Techniques 1 and 2 aimed to investigate the case where SBD was 
assumed to be the default (theoretical) value. Techniques 3 and 4 
aimed to investigate the case where the measured flow velocity 
from the phase contrast MRI (PC‐MRI) data provided an inde-
pendent estimation of the SBD that is close (but not identical) to 
the simulated SBD value. For all experiments, the relative error 
was computed by dividing the absolute value of the difference 
between the estimated value and the simulated value by the sim-
ulated value using the following equation (Equation 5):
The mean and the standard deviation of the relative errors 
were reported.
Experiment 3 investigated the accuracy of ATT estima-
tion using Turbo‐QUASAR when a prolonged ATT was 
expected. In this case, the simulated ATT values were set 
to be 0.8, 1.0, and 1.2 seconds and CBF and SBD were 
60 mL/100 g/min and 0.6 seconds, respectively. Noise was 
added using the SNR values of 5, 10, 50, and 100. The 
mean and standard deviation of the estimated ATT were 
computed.
3.2 | Healthy cohort data
All procedures were approved by the local institutional 
review board of the Amsterdam University Medical Centers, 
Location Academic Medical Center, The Netherlands. The 
procedures were carried out according to the Declaration of 
Helsinki. Data were analyzed from a study in which 11 healthy 
volunteers (mean age 39 ± 17 years, 5 female) were included 
after they had given written informed consent.19 Exclusion 
criteria were contraindications to MRI and acetazolamide, 
history of stroke, brain injury, neurological disease, and 
injury that might affect cerebral autoregulation. Each subject 
underwent antecubital placement of a venous cannula and 
MRI with acetazolamide administration. Acetazolamide 
was administered at a dose of 16 mg/kg body weight with 
a maximum of 1400 mg. All images were acquired on a 
clinical 3.0T MR system (Ingenia; Philips Healthcare, Best, 
The Netherlands) with a 32‐channel receive head‐coil and 
body‐coil transmission.
The following MR image series were collected from 
each subject: (1) baseline—3D T2‐FLAIR (fluid‐attenu-
ated inversion recovery), 2D PC‐MRI, Turbo‐QUASAR; (2) 
PCASL, acquired immediately before, during, and after ac-
etazolamide administration; and (3) postacetazolamide ad-
ministration: PCASL calibration M0, Turbo‐QUASAR, and 
2D PC‐MRI. Table 3 lists the parameter values of the MRI 
data. PCASL and Turbo‐QUASAR imaging volumes were 
planned identically such that the middle slice of each volume 
corresponded to the same slice in both scans. Supporting 
Information Figure S1C,D shows the pulse sequence dia-
gram of Turbo‐QUASAR. Similar to QUASAR,2 crushing 
gradients with three different directions were applied in 
Turbo‐QUASAR before the Look‐Locker acquisition. Data 
collected with the crushing gradients were considered to 
represent signal from the brain tissue, and data from with-
out the crushing gradients were signals from both the tissue 
and the arterial blood (macrovasculature). Each repeat of 
Turbo‐QUASAR consisted of seven dynamics with six of 
them acquired using the normal flip angle (35°) and one 
using the low flip angle (11.7°) as described in Chappell 
et al.16 Among the six dynamics of normal flip angle, four 
of them were acquired with the crushing gradients and two 
without the crushing gradients. In the dynamics of low 
flip angle, crushing gradients were not used. In the in vivo 
Turbo‐QUASAR data of this study, two repeats were ac-
quired, making the full data include eight dynamics with the 
crushing gradients and six dynamics without the crushing 
(5)Errorrelative =
||Xestimated −Xsimulated||
Xsimulated
×100%
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gradients. The order of the slices acquired in these two re-
peats was different, as explained in Supporting Information 
Figure S1. The first 35 repeats (dynamics) of PCASL were 
used as baseline scans. At repeat 35, acetazolamide was ad-
ministered. The last 35 repeats were used as postacetazol-
amide scans, assuming the effect of acetazolamide reached 
a plateau 10 to 15 minutes after injection.20 The imaging 
slice of the PC‐MRI and the labeling plane of PCASL were 
planned at the same location (90 mm below the center of the 
PCASL imaging volumes), and it was placed perpendicular 
to the vessels in the neck at cervical level C1.
3.3 | Blood flow velocity quantification
PC‐MRI images were segmented manually to measure the 
average velocity of the arterial blood in each vessel in the la-
beling region. This included the left and right internal carotid 
arteries and vertebral arteries. Measuring velocity in these 
arteries served two purposes: (1) to estimate the bolus du-
ration of Turbo‐QUASAR and (2) to estimate the inversion 
efficiency of PCASL.
3.4 | Absolute CBF quantification of Turbo‐
QUASAR
For each subject, estimation of the effective SBD of both 
pre‐ and postacetazolamide conditions was performed 
using the mean flow velocity of the arterial blood in both 
internal carotid arteries from the PC‐MRI data. The esti-
mated SBD value () was either (1) assumed to be equal 
to the time between each acquisition (ΔTI) if the estimated 
flow velocity was equal to or less than the velocity thresh-
old (v0 =25 cm∕s) set for the width of the labeling slab
13 or 
(2) computed using the width of the labeling slab and the 
mean measured flow velocity, using the following formula-
tion (Equation 6):
Subsequently, the bolus duration of Turbo‐QUASAR of both 
pre‐ and postacetazolamide was computed by summing the 
duration of all sub‐boluses.
For each subject, CBF and ATT of Turbo‐QUASAR in 
both pre‐ and postacetazolamide conditions were estimated 
by fitting the tissue kinetic model (Equation 4) to the data of 
the tissue component using the spatial Variational Bayesian 
inference technique21,22 and the parameter values in Table 2. 
All Turbo‐QUASAR control data were used in estimating 
the calibration M0 data using the technique described in the 
Theory section. The inversion efficiency and blood‐water par-
tition coefficient were assumed to be identical to the values 
used in the QUASAR study (0.91 and 0.98, respectively).23
(6)𝜏 =
{
ΔTI, v≤ v0
L
v
, v> v0
T A B L E  3  Imaging parameters of the MRI data
Parameter Value
3D T2‐FLAIR
TE/TR (ms) 356/4800
T2 prep TE (ms) 125
Matrix/FOV 256 × 256 × 321/250 × 250 × 180
Voxel size (mm) 0.98 × 0.98 × 1.12
IR delay (ms) 1650
Scan duration (min) 5:07
2D PC‐MRI
TE/TR (ms) 5.5/15
Flip angle (degrees) 15
Matrix/FOV 512 × 512/230 × 230
Voxel size (mm) 0.45 × 0.45 × 4
Scan duration (min) 1:02
Turbo‐QUASAR
TE/TR (ms) 16/6000
TI (ms) 40, 640, …, 6340
ΔTI (ms) 600
Flip angle (degrees) 35, 11.7
Matrix/FOV 64 × 64/240 × 240
Voxel size (mm) 3.75 × 3.75 × 7
Width of labeling slab (L) (cm) 15
No. of sub‐boluses 6
No. of slices 15
Slice acquisition time (ms) 36
Repeats 2
Vascular crushing VENC (cm/s) 4
Scan duration (min) 3:24
PCASL
TE/TR (ms) 14/4400
PLD (ms) 1800
Bolus duration (ms) 1800
Matrix/FOV 80 × 80/240 × 240
No. of slices 19
Slice acquisition time (ms) 42.1
Voxel size (mm) 3 × 3 × 7
Repeats 140
Scan duration (min) 20:39
PCASL M0
TE/TR (ms) 14/4400
Matrix/FOV 80 × 80/240 × 240
Voxel size (mm) 3 × 3 × 7
No. of slices 19
Repeats 6
Scan duration (min) 0:26
FOV = field of view; IR = inversion recovery; VENC = velocity encoding.
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3.5 | Absolute CBF quantification of PCASL
The efficiency of flow driven inversion in PCASL 
was simulated in Matlab (2016; The Mathworks, Inc., 
Natick, MA) by solving the Bloch equations using matrix 
representation.24 “Balanced” PCASL settings were: gradient 
(Gmax = 5.0 mT/m, Gave = 0.36 mT/m) and RF pulse train 
(Hanning shaped RF pulses of 0.48‐ms duration and 1.21‐ms 
spacing, flip angle 27.81°), consistent with the labeling train 
parameters implemented in the scanner. To reflect a realistic 
distribution of flow velocities, a laminar flow profile was 
assumed and appropriate velocity weighting performed as 
proposed by Maccotta et al24 (Equation 7):
Simulations were performed for vmax values ranging from 1 to 
100 cm/s with 1‐cm/s step size. Efficiency was measured at the 
spin location 3 cm away from the labeling plane and the time 
it took to cover that distance used for T1 relaxation correction. 
For each subject, the mean velocity in each vessel was computed 
from the acquired PC‐MRI data. The effective inversion effi-
ciency of each subject was computed by summing the inversion 
efficiency of each vessel and weighted by the fraction of blood 
volume contributed by each vessel out of the total volume.19
CBF was estimated using the spatially regularized 
Variational Bayesian inference technique in the FSL tool 
BASIL21,22 assuming a fixed ATT of 1300 ms and the esti-
mated inversion efficiency for each subject before and after 
the administration of acetazolamide. The parameter values 
used in model fitting are shown in Table 2. For calibration, 
given that the TR of the M0 image of PCASL was shorter 
than 5s, the signal intensity was corrected by multiplying by a 
factor of 1∕(1−e−TR∕T1,Tissue ), where the T1,Tissue value was cho-
sen to be 1300 ms (same with the value used in model fitting) 
for the whole brain.3 The partial volume effects on the edge 
of the calibration image were corrected using the erosion and 
extrapolation technique.25 Finally, the estimated CBF images 
were calibrated voxelwise by the corrected M0a.
For both Turbo‐QUASAR and PCASL, CVR in each 
voxel was computed using the absolute CBF values of base-
line and acetazolamide conditions by the following equation 
(Equation 8):
3.6 | Turbo‐QUASAR and PCASL data 
quality assessment
The quality of the Turbo‐QUASAR and PCASL data was 
assessed at the baseline condition using the CoV of the 
estimated CBF maps. For each voxel, the Variational 
Bayesian inference technique models the unknown CBF 
as a distribution and provides an estimation of the mean 
and standard deviation of this distribution.21 The CoV was 
defined as the ratio between the standard deviation and the 
mean of the estimated CBF. The mean CoV of all the voxels 
was computed for the Turbo‐QUASAR and PCASL data of 
each subject. Only the first 25 repeats of the PCASL baseline 
data were used to compute the CoV in order to match the 
acquisition time of Turbo‐QUASAR (3.5 minutes). A 
low CoV value indicates that the estimated CBF has low 
variability and high confidence.
The SNRs of Turbo‐QUASAR and PCASL data were 
compared at baseline condition. For Turbo‐QUASAR, noise 
was estimated by computing the standard deviation of the re-
siduals of the model‐fit across all the TIs of the in vivo data. 
The signal was defined as the ASL difference signal ex-
pected at TI = 3.63 seconds (maximum signal) when CBF = 
60 mL/100 g/min and ATT = 0.7 seconds and using the esti-
mated M0 of each subject. For PCASL, noise was estimated 
by computing the standard deviation of the residuals of the 
model fit of the first 25 repeats (matching the same acqui-
sition time with Turbo‐QUASAR) of the in vivo data. The 
signal was defined as the expected ASL difference signal at 
PLD = 1.8 seconds by assuming CBF = 60 mL/100 g/min 
and ATT = 1.3 seconds and using the M0 value of each 
subject.
3.7 | Statistical analysis
Two‐tailed paired t tests were conducted to compare the 
global and regional (voxel‐wise) CBF and CVR between the 
various quantification techniques. All CBF and CVR maps 
were transformed to the standard Montreal Neurological 
Institute (MNI)152 space by combining the rigid‐body 
transformation matrix of the ASL difference data to the 
T2‐FLAIR structural image of each subject and a second 
transformation matrix obtained by registering the T2‐FLAIR 
image to the MNI152 2‐mm standard brain using the FSL 
tool FLIRT.26 Given that the coverage of Turbo‐QUASAR 
was slightly smaller than PCASL, a mask for group analy-
sis was created using the coverage of Turbo‐QUASAR by 
taking space covered by all subjects. Before each t test, all 
images were smoothed using a Gaussian spatial filter of 
5‐mm full width at half maximum. Tests were conducted 
using the FSL tool RANDOMISE with 5000 permuta-
tions27,28 under the null hypothesis that the CBF or CVR 
values were the same. Family‐wise error rate was corrected 
using the method developed by Holmes et al,29 and the cor-
rected P value was recorded and thresholded at 0.05 for 
significance. Voxel‐wise CBF and CVR differences in 
standard space were computed for each test.
(7)=
1
2v2
max
vmax
∫
0
v ⋅  (v) dv
(8)CVR=
CBFAcetazolamide−CBFBaseline
CBFBaseline
×100%
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4 |  RESULTS
4.1 | Simulated experiments
Figure 2A shows the estimated CBF using the model‐based 
method from the simulated Turbo‐QUASAR data with a 
different number of sub‐boluses. The estimated mean CBF 
was consistently accurate at 60 mL/100 g/min for SNR = 10. 
With more sub‐boluses created, which increased the signal, 
the standard deviation of the estimated CBF reduced, but it 
plateaued after four sub‐boluses. Figure 2B shows the rela-
tive error between the estimated parameters and the simu-
lated values when the simulated SBD was varied. Overall, the 
model‐based technique was accurate in estimating CBF and 
ATT if the correct SBD was supplied to the model‐fitting al-
gorithm. In default SBD, where we attempted to estimate the 
effective SBD directly from the data in model fitting assum-
ing a default  value of 600 ms as the prior, the results were 
only accurate if the prior matched the simulated value (black 
line). Model fitting alone was not able to correct fully for 
variation in SBD, although it offered some improvement at 
higher SNR than simply taking the default value alone (i.e., 
improvement from step 1 to step 2). In corrected SBD, where 
the prior of the SBD was a closer match to the simulated 
SBD, greater accuracy could be achieved. Figure 2C shows 
the estimated ATT values at different SNRs. The accuracy of 
ATT estimation was only slightly affected by SNR.
4.2 | CBF and CVR quantification of 
healthy cohort data
Figure 3 shows the estimated CBF of an example subject using 
Turbo‐QUASAR and PCASL before and after acetazolamide 
administration. The slightly lower resolution of the Turbo‐
QUASAR acquisition could be observed in the smoother 
appearance of the CBF maps in this case. Figure 4A shows 
the mean whole‐brain CBF of all subjects at baseline and after 
acetazolamide administration. Overall, both Turbo‐QUASAR 
and PCASL were sufficiently sensitive to detect significant 
CBF changes in this population after the administration of 
acetazolamide. At baseline, the mean CBF of the whole brain 
were between 45 and 50 mL/100 g/min for both methods. 
After the administration of acetazolamide, the mean CBF of 
the group increased significantly to between 75 mL/100 g/
min and 77 mL/100 g/min for all methods. No significant 
CBF differences were observed between Turbo‐QUASAR and 
PCASL at both baseline and postacetazolamide conditions. The 
Turbo‐QUASAR difference data and the model‐fitting results 
of an example voxel in Turbo‐QUASAR data can be found in 
Supporting Information Figure S3.
Figure 4B shows the mean whole‐brain CVR of the two 
ASL methods across the group, and Figure 5 shows the mean 
voxel‐wise CVR images. The mean CVR of the group was 
between 63% and 64% for the different ASL techniques, but 
they were not significantly different. For both ASL tech-
niques, the CVR of the posterior regions of the brain ap-
peared to be higher than the other regions.
Figure 6 shows the results of the paired t tests and the 
regional CBF differences (with corrected P value <0.05) 
between the two ASL methods before and after the admin-
istration of acetazolamide. Before the administration of ac-
etazolamide, CBF of Turbo‐QUASAR in deep gray matter 
structures was significantly higher than the CBF of PCASL. 
The regional CBF differences increased after the administra-
tion of acetazolamide and were dominated by regions with 
higher CBF as estimated by Turbo‐QUASAR (hot colors).
Figure 7 shows the changes in the mean ATT estimated by 
Turbo‐QUASAR, changes in mean blood velocity in the inter-
nal carotid artery, resulting estimate of inversion efficiency for 
PCASL, mean CoV of the two ASL data sets, and estimated 
SNR of Turbo‐QUASAR and PCASL. Overall, the mean ATT 
decreased significantly by 10% postacetazolamide. In terms 
of the velocity in the internal carotid artery, the mean value 
for the baseline and acetazolamide conditions were 24.0 and 
33.5 cm/s respectively, with a significant increase of 37%. 
From the Bloch equation simulations, this translated into a 
mean predicted increase in inversion efficiency from 0.84 
to 0.88 for PCASL postacetazolamide. The increase in flow 
velocity also caused the mean SBD of Turbo‐QUASAR to 
decrease significantly from 0.58 to 0.46 seconds (21%) after 
the administration of acetazolamide. The estimated CoV of the 
Turbo‐QUASAR data was significantly higher (34%) than 
PCASL at baseline, implying that the estimated CBF of 
Turbo‐QUASAR had a higher variability and the CBF esti-
mation from PCASL had a higher precision than the CBF 
estimated from Turbo‐QUASAR. The mean SNR of Turbo‐
QUASAR was also significantly lower than that of PCASL, 
as shown in Figure 7E. The median across subjects of the 
SNR of PCASL (3.6) was significantly higher than Turbo‐
QUASAR (3.1). Bland‐Altman plots showing the mean and 
difference between the CBF of Turbo‐QUASAR and PCASL 
can be found in Supporting Information Figure S4.
5 |  DISCUSSION
In this work, we have developed a model‐based method 
for estimating the hemodynamic parameters from Turbo‐
QUASAR ASL and investigated its application for measur-
ing CBF and CVR. The objective of the recently developed 
Turbo‐QUASAR technique was to include a frequent labeling 
scheme to achieve a higher SNR while retaining the measure-
ment of ATT using a multi‐TI acquisition. In the simulations, 
the accuracy of the model‐based method for CBF estima-
tion was evaluated to address the question of sensitivity to 
variation in bolus duration that might be brought about by 
changes in arterial blood velocity. We compared absolute 
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F I G U R E  2  Results of simulated experiments. (A) Experiment 1: estimated CBF values for the different number of sub‐boluses (simulated 
CBF = 60 mL/100 g/min). (B) Experiment 2: relative error between estimated and simulated values when the simulated SBD was varied. In default 
SBD, the errors were low only when the SBD was equal to the global value. In corrected SBD, the accuracy of the estimation was predominantly 
affected by the SNR. (C) The estimation of ATT was only affected by SNR
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CBF and CVR quantification from a healthy cohort data ac-
quired using single‐PLD PCASL and Turbo‐QUASAR. The 
primary findings were: (1) The model‐based quantification 
method demonstrated good accuracy and consistency when 
the effective SBD is known, although fitting errors appeared 
if the true SBD was sufficiently shorter than expected; (2) 
both Turbo‐QUASAR and single‐PLD PCASL achieved sim-
ilar whole‐brain CBF and CVR values; and (3) there were 
significant regional CBF differences in deep gray matter 
structures measured by the two ASL techniques.
5.1 | Model‐based method and simulations 
for Turbo‐QUASAR
The model‐based method adopted here was accurate in esti-
mating the hemodynamic parameters if the flow velocity of 
the arterial blood was normal (black curve of default SBD in 
Figure 2B), but it was limited by large deviations from the ex-
pected SBD value. If the SBD became shorter, such as might 
be expected under more rapid blood velocity in CVR stud-
ies, the estimation of all parameters (CBF, ATT, and SBD) 
became less accurate (default SBD in Figure 2B). The issue 
could be partially resolved by incorporating an estimated 
SBD in the model‐fitting procedure (corrected SBD in Figure 
2B). This implies that where variation in arterial blood ve-
locity is expected, it will be necessary to supply a separate 
estimate of the effective SBD for the accurate quantification 
of CBF. Further investigation indicated that the difficulty in 
simultaneously estimating CBF, ATT, and SBD with high 
accuracy is challenging because of the correlation between 
these three parameters in their effect on the resulting kinetic 
curve.
F I G U R E  3  CBF maps of an example subject before and after the administration of acetazolamide. Overall, CBF increased after the 
administration of acetazolamide
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5.2 | Comparison with PCASL in CBF 
quantification
In a healthy cohort, the full‐brain CBF estimated from the 
data collected by Turbo‐QUASAR was similar to that from 
single‐PLD PCASL (between 45 and 50 mL/100 g/min 
at baseline and 75 and 77 postacetazolamide). Although 
the results of the Turbo‐QUASAR method appeared to 
contain higher intersubject variations, the whole‐brain 
CBF was not significantly different from the results of 
PCASL in this population. The lower SNR (reflected by 
the higher CoV in Figure 7D) of Turbo‐QUASAR may be 
an important factor in explaining the higher intersubject 
variations observed in the Turbo‐QUASAR results. 
Despite the high variability in CBF quantification, Turbo‐
QUASAR has the advantage over single‐PLD PCASL in 
that it can be used to measure ATT, as well as quantify 
the absolute CBF without acquiring a separate calibration 
data.23 The mean baseline ATT of the cohort was between 
0.8 and 0.85 seconds (Figure 7A), in agreement with the 
literature.4 The CBF maps of Turbo‐QUASAR showed less 
contrast between gray and white matter than the results of 
PCASL, as seen in Figure 3. This may be a result of the 
lower spatial resolution of Turbo‐QUASAR (3.75 × 3.75 × 
7 mm3) compared to PCASL (3 × 3 × 7 mm3), which would 
lead to more partial volume effects.
In the calibration of PCASL data, the partial volume 
effects in different brain tissues were not considered and a 
global T1,tissue of 1300 ms was assumed to correct the short TR 
of the M0 image following the work by Alsop et al.
3 In reality, 
there will be partial voluming of white matter, gray matter, 
and cebrebrospinal fluid within the M0 image, which we have 
not attempted to correct for here. Correction is possible using 
partial volume estimates either derived from the T1‐weighted 
structural image, but reliant on a good registration, or from 
partial volume estimates made in the ASL space, for example 
derived from the saturation recovery of the Turbo‐QUASAR 
control images using the method in Zhao et al.25 This might 
alter some of the perfusion values noted in this study, but not 
the conclusions related to comparisons between PCASL and 
Turbo‐QUASAR.
Both before and after the administration of acetazolamide, 
a common feature of the regional CBF comparison was that 
there were no significant CBF differences for Turbo‐QUASAR 
and PCASL in cortical gray matter (Figure 6), where most 
ASL signal can be found. However, some regions of white 
matter and deep gray matter structures, which would have 
particularly prolonged ATT, showed significant differences, 
although the lower perfusion or SNR in the white matter 
makes this harder to interpret with confidence. It is possible 
therefore that the systematic differences observed between the 
two methods were associated with ATT. However, the size of 
the differences, which were of the order of 25 mL/100 g/min, 
would be larger than explained by ATT alone. Further investi-
gation may be needed to resolve the CBF discrepancy in deep 
gray matter between Turbo‐QUASAR and PCASL.
ATT quantification has been investigated by several studies 
using different ASL techniques. In a study using multi‐PLD 
PCASL on healthy subjects, Qin et al reported a mean ATT 
of 1.4 ± 0.3 seconds for the whole brain,30 which overlapped 
with the range of ATT found in our study. A similar multi‐PLD 
PCASL technique has also been applied in a reproducibil-
ity study in which the researchers demonstrated a consistent 
measurement of ATT in the same session (interclass correla-
tion = 0.908) using the same Variational Bayesian inference 
approach utilized in the present study.31 As for the ATT quan-
tification after the administration of acetazolamide, although 
it is challenging to compare the present results with the litera-
ture because of the different vasoactive stimuli administered, 
a number of studies have been conducted to demonstrate the 
F I G U R E  4  (A) Mean CBF of all subjects before and after 
acetazolamide administration. For all methods, the CBF increased 
significantly after acetazolamide administration. (B) Mean CVR of the 
group. For both ASL techniques, the mean CVR values of the group 
were between 63% and 64% but not significantly different from each 
other. Each box plot indicates the median, 25th, and 75th percentiles, 
maximum and minimum not considering outliers, and the outliers 
represented by the “+” symbol
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reduction in ATT after the administration of vessel dilation 
stimuli. For instance, Macintosh et al demonstrated a signif-
icant reduction in ATT by 12% after the administration of 
remifentanil using a multi‐TI PASL technique, reflecting the 
sensitivity of PASL to capture ATT variations attributed to 
vessel dilation.32 Donahue et al showed that regional ATT 
decreased between 4.6% and 7.7% measured by a multi‐PLD 
PCASL technique in hypercarbia.7
The comparison of the CBF maps of Turbo‐QUASAR 
and PCASL revealed that there was a significant difference 
in posterior brain regions (Figure 6), in the territory of the 
basilar artery. This may be a function of the effect of ATT, 
which is typically prolonged in this region compared to the 
rest of the brain and is prolonged further by the effects of 
dispersion.33 No attempt was made in the work to account for 
dispersion and the influence of cardiac pulsatility, which will 
potentially manifest in different ways in the quantification of 
CBF from both PCASL and Turbo‐QUASAR data. Although 
several bolus dispersion models have been developed for 
ASL techniques with a single labeling pulse,18,34 a more 
comprehensive analysis is needed to investigate whether 
these models would be effective for the multiple sub‐boluses 
techniques used in Turbo‐QUASAR. Additionally, it remains 
possible that some differences between Turbo‐QUASAR and 
PCASL could arise from the macrovascular signal arising 
from labeled blood‐water in the larger arteries that has yet 
to be delivered to the tissue. This might be expected to be 
more prominent in PCASL at short PLDs and in more infe-
rior slices where larger arteries are located. In theory, this 
is already directly corrected for as a source of contamina-
tion in the Turbo‐QUASAR analysis by using a combina-
tion of crushing gradients applied in different directions.23 
Furthermore, the flow velocity of the vertebral arteries was 
different from carotid arteries, which may have implications 
for quantification for both PCASL and Turbo‐QUASAR, af-
fecting both inversion efficiency and bolus duration.
In CBF quantification using Turbo‐QUASAR data, the 
SBD was estimated using the flow velocity measurement from 
PC‐MRI data. If the flow velocity is greater than the optimal 
value, a shorter SBD would be expected. If the velocity is less 
F I G U R E  5  Estimated mean CVR map for each ASL method. In both Turbo‐QUASAR and PCASL results, the posterior region appeared to 
have the largest CVR. The views include transverse slices of z = 33, 35, …, 61
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than the assumed value of the current implementation, a frac-
tion of the sub‐bolus would still remain in the labeling region 
at the time of the next labeling pulse, leading to this part of the 
sub‐bolus being inverted twice and reducing the duration of 
the effective SBD. In the in vivo experiment, we have primar-
ily focused our investigation on conditions in which a higher 
blood flow velocity was expected because the administration 
of acetazolamide increased the blood flow velocity. In the 
case of slower flow velocity, such as the blood near the vessel 
walls, the SBD would also be shorter than the optimal value. 
Although a potential extension to include the conditions of 
lower blood flow may be desired, it should be noted that the 
bolus dispersion issue would become more significant for the 
slow‐moving spins near the vessel walls and the inversion effi-
ciency must be reconsidered because of the multiple inversion 
of the spins in the sub‐bolus.18 This is something that could be 
pursued using the same framework of this study in the future.
In the in vivo experiment using PCASL, a global ATT 
of 1300 ms was assumed for the CBF quantification. 
The PLD of the single‐PLD PCASL technique was specif-
ically chosen to be insensitive to ATT variations within a 
reasonable range expected in the healthy cohort studied.3 
Using the estimated ATT from the Turbo‐QUASAR data 
and accounting for differences between PCASL and PASL 
labeling by assuming a 500‐ms difference in ATT between 
the two techniques, we would estimate that a <1% differ-
ence in mean CBF might be observed attributable to not 
accounting for ATT in PCASL analysis. Such a discrep-
ancy would reflect the previous findings by Alsop et al 
that CBF quantification should be fairly insensitive to ATT 
variations for PLDs longer than 1800 ms.3
5.3 | Comparison with PCASL in CVR 
quantification
The CVR (Figures 4B and 5) and the statistical tests results 
(Figure 6) indicated that both ASL techniques were suf-
ficiently sensitive to measure CVR. The measured mean 
F I G U R E  6  Regions of significant CBF differences between PCASL and Turbo‐QUASAR (t test; corrected P value <0.05) before and after 
acetazolamide administration. Hot color indicates that CBF of Turbo‐QUASAR is higher, and cold color indicates that CBF of PCASL is higher. 
The views include transverse slices of z = 33, 35, …, 61
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CVR was between 63% and 64% for this population, which 
is within the range of the values measured by Positron 
Emission Tomography using 15O‐water as the tracer and 
acetazolamide as the stimulus.35,36 Additionally, Turbo‐
QUASAR offered the opportunity to measure changes in 
ATT with a mean reduction of 10% observed in this popu-
lation (Figure 7A). Similar observations of a significant 
ATT decrease have been reported in CVR studies in which 
subjects experienced hypercarbia.7 Global CVR values 
measured by Turbo‐QUASAR demonstrated a higher in-
tersubject variability than PCASL (Figure 4B), similar to 
the large intersubject variability noted in the CBF results 
(Figure 4A). Again, this might be explained by the lower 
SNR of Turbo‐QUASAR as indicated by the significantly 
higher CoV than PCASL (Figure 7D).
In quantifying the CVR values from PCASL data, the in-
version efficiency was estimated using the PC‐MR data, and 
a significant increase (Figure 7C) was identified after the 
acetazolamide administration. Although such an observation 
may contradict with the belief that the inversion efficiency 
of PCASL should decrease for a higher flow velocity,36  
the present study demonstrated that the velocity dependency 
of the inversion efficiency varied with the PCASL‐labeling 
parameters. The increase in flow velocity also caused the 
SBD of Turbo‐QUASAR to decrease significantly by 21%. 
Without accounting for such variations, the CBF and CVR 
of Turbo‐QUASAR would be 15% and 34% less (both sta-
tistically significant), respectively, than the current values 
after the administration of acetazolamide, leading to an un-
derestimation of these parameters. Therefore, it is crucial to 
incorporate the flow velocity information for the accurate 
quantification of CBF and CVR.
5.4 | Limitations
Throughout the study, we relied on the estimated flow velocity 
of the vessels that were segmented manually from the PC‐MRI 
data. The inversion efficiency of PCASL and the bolus dura-
tion of Turbo‐QUASAR were then estimated using the derived 
velocity values. Although the current results revealed that the 
inversion efficiency increased,37,38 the sensitivity of the inver-
sion efficiency to the estimated velocity remains to be more 
F I G U R E  7  Estimated mean ATT from Turbo‐QUASAR, flow velocity from PC‐MRI, inversion efficiency of PCASL, and mean CoV of 
the two ASL techniques. (A) and (B) The administration of acetazolamide induced a significant decrease in mean ATT by 9.4% and a significant 
increase of mean flow velocity of the arterial blood in the internal carotid artery by 37%, and this led to (C) a significant increase in estimated 
inversion efficiency by 3.5%. (D) The mean CoV of the PCASL data was significantly lower than that of the Turbo‐QUASAR data by 34%. (E) 
Estimated SNR of Turbo‐QUASAR and PCASL. The SNR of PCASL was significantly higher than PCASL
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fully explored, in particular how variations in sequence param-
eters would affect the inversion efficiency. We have not sought 
to investigate all possible SBD variations induced by different 
flow velocities and have concentrated on the case in which the 
SBD was reduced because of a more rapid flow in the CVR 
experiment. A potential extension would be to consider the im-
pact on Turbo‐QUASAR analysis attributable to slower blood 
flow. The range of velocity (from 0 to 100 cm/s) in computing 
the inversion efficiency of the PCASL analysis was chosen in 
order to ensure completeness and coverage of a wide range 
of velocity values. The narrower range of values used in the 
SBD of Turbo‐QUASAR reflected the more realistic values in 
this study. Although we primarily focused our investigation on 
these ranges of SBDs for the healthy cohort of this study, we 
believe that broadly the conclusion would hold based on the 
results of the simulation experiments.
6 |  CONCLUSIONS
In this work, we have developed a model‐based quantification 
technique for estimating hemodynamic parameters using 
Turbo‐QUASAR. The model‐based method demonstrated 
good accuracy and consistency in normal blood flow 
conditions in simulations, but it requires a separate estimate 
of the bolus duration when this deviates substantially from the 
normal value. For CVR quantification, both Turbo‐QUASAR 
and single‐PLD PCASL techniques achieved similar CVR 
measurements between 63% and 64% in a healthy population. 
Therefore, we can conclude that PCASL remains to be the 
favorable choice for CVR measurement because of its low CoV 
whereas Turbo‐QUASAR can serve as an alternative technique 
with the potential benefit of controlling for ATT variations.
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SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.
FIGURE S1 Slice shifting strategy. In repeat 1, slices 
were acquired from bottom to top (slice A to D) in each TI, 
whereas in repeat 2, slices were acquired from middle to the 
top then from bottom to the middle (slice C to D then A to B). 
This effectively increases the number of slices acquired at 
each TI as well as the temporal resolution
FIGURE S2 MT effects in Turbo‐QUASAR. Each curve 
shows the average signal of all the voxels in the slice of the 
corresponding color at different TI. From TI = 1 to TI = 6, the 
signal of the Turbo‐QUASAR control image is affected by both 
MT and Look‐Locker effects. After TI = 6, the signal is only 
affected by the Look‐Locker effect. The signal in the superior 
slice (blue) experiences less influence from the MT effects than 
the signal in the inferior slices (red) attributable to the different 
distance between the slice and the labeling location
FIGURE S3 Turbo‐QUASAR difference data (middle slice) 
at each inversion time and model‐fitting results in an example 
voxel. Note that the data from the 2 TRs were combined using 
the slice‐shifting strategy to increase the effective temporal 
resolution from 11 to 22. The odd number slices were from 
the first TR, and the even number of slices were from the 
second TR. Overall, the ASL signal postacetazolamide was 
higher than the baseline signal, indicating an increase in CBF
FIGURE S4 Bland‐Altman plots of the mean and differences 
of CBF before and after the administration of acetazolamide. In 
both plots, the solid line represents the mean difference between 
the CBF of Turbo‐QUASAR and PCASL. The dashed lines 
represent the 95% confidence interval of the mean difference
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